This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a ...

The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald ...

The latest results from the phase 1b/2 OrigAMI-1 study showed an overall response rate (ORR) of 51% and a median progression-free survival (PFS) of 9.2 months. The data were especially encouraging in ...

Wellcome Sanger Institute Senior Group Leader, and former Institute Director, Professor Sir Mike Stratton has been awarded the 2026 Jessie Stevenson Kovalenko Medal by the Council of the National ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a registrational phase 3 clinical trial of iSCIB1+ for patients with advanced melanoma, a step that ...

The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and ...